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Abstract
Background: The contribution of sex and initial clinical presentation to the long-term outcomes in 
patients undergoing percutaneous coronary intervention (PCI) is still debated. 
Methods: Individual patient data from 5 Korean-multicenter drug-eluting stent (DES) registries (The 
GRAND-DES) were pooled. A total of 17,286 patients completed 3-year follow-up (5216 women and 
12,070 men). The median follow-up duration was 1125 days (interquartile range 1097–1140 days), 
and the primary endpoint was cardiac death at 3 years. 
Results: The clinical indication for PCI was stable angina pectoris (SAP) in 36.8%, unstable  
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ST-segment elevation myocardial (STEMI) in 15.8%. In all groups, women were older and had a higher 
proportion of hypertension and diabetes mellitus compared with men. Women presenting with STEMI 
were older than women with SAP, with the opposite seen in men. There was no sex difference in cardiac 
death for SAP or UAP/NSTEMI. In STEMI patients, the incidence of cardiac death (7.9% vs. 4.4%, 
p = 0.001), all-cause mortality (11.1% vs. 6.9%, p = 0.001), and minor bleeding (2.2% vs. 1.2%,  
p = 0.043) was significantly higher in women. After multivariable adjustment, cardiac death was lower 
in women for UAP/NSTEMI (HR 0.69, 95% CI 0.53–0.89, p = 0.005), while it was similar for STEMI 
(HR 0.97, 95% CI 0.65–1.44, p = 0.884). 
Conclusions: There was no sex difference in cardiac death after PCI with DES for SAP and UAP/ 
/NSTEMI patients. In STEMI patients, women had worse outcomes compared with men; how-
ever, after the adjustment of confounders, female sex was not an independent predictor of mortality.  
(Cardiol J)
Key words: coronary artery disease, percutaneous coronary intervention, drug-eluting 
stent, sex difference, myocardial infarction
Introduction
Although the mortality from coronary artery 
disease (CAD) has decreased due to improved pre-
vention and treatment strategies, it remains one 
of the leading causes of morbidity and mortality 
in men and women worldwide. Previous studies 
have suggested that, compared with men, women 
were at higher risk of worse outcomes following 
percutaneous coronary intervention (PCI), with dif-
ferences in risk factors thought to be the cause [1]. 
Women undergoing PCI tend to be older with 
a significantly higher prevalence of diabetes and 
hypertension. Men are more likely to be smokers, 
and have multivessel disease and higher rates of 
prior myocardial infarction (MI). After adjustment 
of confounding factors, there have been conflicting 
results. Recent studies have suggested that gender 
differences have diminished, possibly through the 
evolution of PCI-related devices and evidence-
-based medical therapy [2, 3]. To date, there are 
only a few studies comparing long-term clinical 
outcomes following PCI with drug-eluting stents 
(DES) between men and women in different clini-
cal presentations. Therefore, we aimed to examine 
gender differences in long-term clinical outcomes 
according to clinical presentation following PCI 
with DES.
Methods
The GRAND-DES registry is a patient-lev-
el pooled registry consisting of 17,286 patients 
from 5 separate clinical trials: the Efficacy of 
Xience/Promus versus Cypher in rEducing Late 
Loss after stENTing (EXCELLENT) registry 
(NCT00698607), the Registry to Evaluate the 
Efficacy of Zotarolimus-Eluting Stent (RESO-
LUTE-KOREA) (NCT00960908), the Efficacy and 
Safety of Xience in Coronary artEry Disease aLL-
comers After stenting Using the PRIME Platform 
(EXCELLENT-PRIME) registry (NCT01605721), 
the Harmonizing Optimal Strategy for Treatment 
of coronary artery disease using a BIOLIMUS 
A9-eluting stent (HOST-BIOLIMUS-3000-Korea) 
registry, and the Harmonizing Optimal Strategy 
for Treatment of coronary artery disease using 
a RESOLute INTEgrity (HOST-RESOLINTE) 
registry (Fig. 1). The individual trial designs and 
primary results have been published previously 
[4–6]. Each trial included in this analysis complied 
with the Declaration of Helsinki, and the study pro-
tocols were approved by the Institutional Review 
Board at each participating center. All patients 
provided written informed consent for participa-
tion in each study.
The primary endpoint of this study was cardiac 
death at 3 years. All-cause death, MI, stroke, clini-
cally driven target lesion revascularization (TLR), 
clinically driven target vessel revascularization 
(TVR), and definite or probable stent thrombosis 
(ST) were defined according to the Academic 
Research Consortium (ARC) definitions, whilst 
bleeding rates were reported according to the 
Thrombolysis in Myocardial Infarction bleeding 
criteria [7]. Decreases in hemoglobin levels of 
5 g/dL or more occurring during hospitalization or 
intracranial hemorrhage were classified as major 
bleeding. Scheduled yearly surveillance was per-
formed routinely after PCI by trained personnel. 
If death occurred, details were obtained through 
review of local and external medical records, death 
certification, telephone contact with patients’ 
family, and external providers. Experienced data 
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analysts recorded the details of each death and 
performed initial classification. 
Statistical analysis
We compared the baseline characteristics, 
treatment, and clinical outcomes between women 
and men. Baseline characteristics were reported 
as percentages for categorical variables and means 
with standard deviation (SD) for continuous vari-
ables. Comparisons between groups were made 
either by Pearson’s c2 test for baseline categorical 
variables or Student’s t-test for continuous vari-
ables, as appropriate. In the comparison of clinical 
outcomes among groups, the cumulative incidences 
of the primary and secondary endpoints were es-
timated using the Kaplan-Meier method, and the 
curves were compared using the log-rank test. Cox 
proportional hazard survival models were applied 
for risk comparison between groups. For multivari-
able analysis, the covariates included in the analy-
sis were age, clinical risk factors, and angiographic 
and procedural risk factors. To assess the effect 
of confounders different models were compared. 
Model 1 was the adjusted model with age only. 
Model 2 was adjusted with clinical risk factors such 
as hypertension, diabetes, dyslipidemia, smoking, 
prior MI, prior PCI, prior congestive heart failure, 
and prior peripheral vascular disease in addition to 
model 1. Model 3 was adjusted with angiographic 
risk factors such as multivessel disease, left main 
disease, bifurcation, long lesion, number of stents, 
stent diameter, stent length, and glycoprotein IIb/ 
/IIIa inhibitor and intravascular ultrasound use, 
in addition to model 2. The independent predic-
tors of primary outcome were also obtained by 
multiple Cox regression analysis. All analyses 
were performed using R statistical software 3.6.1 
(R foundation for Statistical Computing, Vienna, 
Austria). All p values were two sided, and a value 
of < 0.05 was considered statistically significant.
Results
A total of 17,286 patients from 5 Korean multi-
center DES registries were enrolled in the current 
GRAND-DES registry. Of these patients, 997 died at 
3-year follow-up. Figure 1 shows the flow of patients 
entered into the study. The study cohort was made 
up of 5216 (30.2%) women and 12,070 (69.8%) men, 
with the clinical indication for PCI stable angina 
pectoris (SAP) in 36.8%, unstable angina pectoris 
(UAP) or non-ST-segment elevation myocardial 
infarction (NSTEMI) in 47.4%, and ST-segment 
elevation myocardial infarction (STEMI) in 15.8%.
Table 1 shows the clinical characteristics of 
the study population according to sex and clinical 
presentation. In all three groups, women were 
older and had a higher proportion of hypertension 
and diabetes and a lower rate of current smoking. 
Women presenting with SAP or UAP/NSTEMI 
were less likely to have had a previous MI or PCI 
and more likely to have a history of congestive 
heart failure, while no such differences occurred 
in the STEMI group. In terms of medication at 
discharge, calcium channel blockers were used 
more frequently in women in all three groups. 


































Figure 1. Study flow chart; NSTEMI — non-ST elevation myocardial infarction; SAP — stable angina pectoris; STEMI 
— ST-segment elevation myocardial infarction; UAP — unstable angina pectoris.
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Other medications were optimally prescribed, with 
respective rates of acetylsalicylic acid, clopidogrel, 
and statin use > 95%, > 93%, and > 82% in all three 
groups. In the comparison of clinical presentations 
within the same sex, age rose incrementally from 
SAP to STEMI for women whereas it fell for men. 
The proportion of current smokers was highest in 
STEMI patients for both women and men. Of note, 
previous PCI was highest in SAP patients for both 
sexes. The population pyramids of age according to 
clinical presentation are shown in Figure 2. The dif-
ferences between women and men were clearly seen, 
especially for STEMI patients. Within each sex group, 
59.6% were older than 70 years for women compared 
with 19.9% for men, among STEMI patients.
Compared to men, women had a lower preva-
lence of multivessel disease in SAP (56.2% vs. 
59.2%, p = 0.017) and a higher prevalence in 
STEMI (60.1% vs. 51.5%, p < 0.001). Multivessel 
disease was most frequent in the STEMI group in 
women, and in the SAP group in men. Left main 
disease was more common in men compared with 
women and was seen least frequently in the STEMI 
group for both sexes. Women had a smaller stent 
diameter in all three clinical presentations. Stent 
diameter and stent length were similar irrespec-
tive of clinical presentation for women. However, 
for men, stent diameter was highest and stent 
length shortest in the STEMI group compared to 
the other groups. Glycoprotein IIb/IIIa inhibitors 
were used predominantly in STEMI for both sexes, 
and among these STEMI patients they were used 
less in women (8.0% vs. 12.0%, p = 0.009). Intra-
vascular ultrasound was used more in men for all 
clinical presentations, with usage lowest in STEMI 
for both women and men. Overall first--generation 
sirolimus-eluting stents were used in 13.1%, whilst 
new-generation DESs were used in the remain-
ing 87.8% of the population. The type of stents 
implanted were similar for all groups (Table 2).
A comparison of the primary endpoint and clini-
cal outcomes at 3 years according to sex and clinical 
presentation is shown in Table 3. The rate of the 
primary endpoint, cardiac death, was highest in the 
STEMI group for both sexes, with the rate signifi-
cant higher in women (7.9% vs. 4.4%, p = 0.001). 
Similarly, all-cause death occurred most frequently 
in the STEMI group for both sexes, with rates 
Figure 2. Population of age according to clinical presentation; A. Overall; B. Stable angina pectoris (SAP); C. Unstable 
angina pectoris/non-ST-segment elevation myocardial infarction (UAP/NSTEMI); D. ST-segment elevation myocardial 
infarction (STEMI).
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higher in women (11.1% vs. 6.9%, p = 0.001). Stent 
thrombosis was similar between the sexes for all 
three groups; however, it was highest in the STEMI 
group among men. Rates of TLR and TVR were 
similar between women and men, and similar among 
initial clinical presentations. Although there was no 
difference in major bleeding according to either sex 
or clinical presentation; minor bleeding occurred 
more frequently in female STEMI patients compared 
with men. Among women, minor bleeding rates 
were highest in patients with STEMI compared to 
SAP and UAP/NSTEMI patients.
The Kaplan-Meier survival curves for cardiac 
death, all-cause death, stent thrombosis, TLR, 
major bleeding, and minor bleeding are shown in 
Figure 3. Among the six groups, according to sex 
Figure 3. Survival curves according to sex and clinical indication; A. Cardiac death; B. All-cause death; C. Stent 
thrombosis; D. Target lesion revascularization; E. Major bleeding; F. Minor bleeding; NSTEMI — non-ST-segment 
elevation myocardial infarction; SAP — stable angina pectoris; STEMI — ST-segment elevation myocardial infarction; 
UAP — unstable angina pectoris.
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and clinical presentation, women in the STEMI 
group had the highest risk of cardiac death, all-
cause death, and minor bleeding.
To assess the effect of confounders on the 
primary endpoint, different models were compared 
in Figure 4. In each clinical presentation, all three 
models showed similar results, with age the domi-
nant factor in the multivariable analysis. In SAP 
patients, before and after adjustment, there was no 
sex difference. In UAP/NSTEMI, the unadjusted 
results showed no difference between the sexes 
(hazard ratio [HR] 1.16, 95% confidence interval 
[CI] 0.91–1.48, p = 0.226), but the adjusted results 
showed a lower risk of the primary endpoint in 
women (HR 0.69, 95% CI 0.53–0.89, p = 0.005). In 
STEMI patients, women had a higher risk of crude 
outcomes (HR 1.84, 95% CI 1.29–2.62, p = 0.001); 
however, the adjusted results showed a similar 
degree of risk between women and men (HR 0.97, 
95% CI 0.65–1.44, p = 0.884). The adjusted results 
of all outcomes are shown in Figure 5 using model 2. 
For SAP patients, women had a lower risk of 
all-cause death (HR 0.57, 95% CI 0.44–0.74, p < 
< 0.001). For UAP or NSTEMI patients, both all-
cause death (HR 0.66, 95% CI 0.54–0.81, p < 0.001) 
and cardiac death (HR 0.69, 95% CI 0.53–0.89, 
p = 0.005) had a lower risk in women. Note that 
for STEMI patients, no sex differences were found 
for any clinical outcomes after adjustment. Table 4 
shows the independent predictors for each clinical 
presentation. Female sex was an independent pre-
dictor in UAP/NSTEMI patients but not in SAP and 
STEMI patients. Age and diabetes were common 
independent predictors among the three clinical 
presentation groups.
Discussion
We investigated the prognostic impact of sex 
differences in CAD patients after PCI with DES ac-
cording to clinical presentation. The main findings 
of the current study are: (1) In the comparison of 
clinical presentations within the same sex, women 
presenting with STEMI were older than those with 
SAP, with the opposite being true among men; 
(2) In SAP or UAP/NSTEMI patients, there were 
no differences in crude clinical outcomes between 
women and men; however, in STEMI patients, 
women had higher rates of all-cause death, cardiac 
death, and minor bleeding than men; (3) After mul-
tivariable analyses there were similar outcomes 
between the sexes in STEMI patients.
In our study, women were older than men 
regardless of clinical presentation, as seen in all 
previous PCI [8–11] or STEMI studies [12, 13]. In 
addition, the stepwise increase of age in women, 
Figure 4. Model comparison of adjusted risk for primary endpoint. The following covariates were sequentially included 
in the adjusted models: Model 1: age only; Model 2: Model 1 + clinical risk factors; Model 3: Model 2 + angiographic 
and procedural factors; CI — confidence interval; HR — hazard ratio; NSTEMI — non-ST-segment elevation myocar-
dial infarction; SAP — stable angina pectoris; STEMI — ST-segment elevation myocardial infarction; UAP — unstable 
angina pectoris.
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and the corresponding decrease of age in men, from 
SAP to STEMI is also similar to previous studies 
[14, 15]. The age differences between women 
and men were 4.7, 6.8, and 11.4 years for SAP, 
UAP/NSTEMI, and STEMI, respectively. Women 
diagnosed with STEMI were approximately 10 to 
14 years older than men [15–17]. As seen in the 
model comparison of adjusted risk for the primary 
endpoint, age played a dominant role in the progno-
sis of future events. In our previous observational 
study of plaque characteristics of culprit lesions in 
STEMI, elderly women had an increased number 
of vulnerable plaques, implying a lower protective 
effect of estrogen due to postmenopausal states 
[16]. A more diffuse pattern of atherosclerosis 
was observed in women compared to focal lesions 
in men [18, 19]. When women get older, a focal 
obstructive lesion within this diffuse atheroscle-
rosis may result in acute MI. Since plaque erosion 
is more frequent in women compared with plaque 
rupture [20], more NSTEMIs may be expected than 
STEMIs in women compared to men. In our study, 
the NSTEMI population was made up of 55.4% 
women and 44.4% men. Furthermore, the diffuse 
progression of plaque in women could explain the 
older age of female STEMI patients compared to 
those with SAP. Among STEMI patients, the pro-
portion with age older than 70 years was 59.6% for 
women and only 19.9% for men. These different 
characteristics of plaque composition and morphol-
ogy could explain the increased risk of STEMI in 
women of older age. 
There is conflicting evidence regarding the 
long-term outcomes after PCI between women and 
men. Previous studies showed better long-term 
survival either in women or in men compared with 
the opposite sex [21–25]. In contrast, other studies 
showed that there is no difference between the 
sexes, although women had worse baseline char-
acteristics [2, 3, 8, 10, 15]. Other studies reported 
Figure 5. Adjusted risk of women according to clinical presentation; CI — confidence interval; HR — hazard ratio; 
MI — myocardial infarction; NSTEMI — non-ST-segment elevation MI; SAP — stable angina pectoris; STEMI — 
ST-segment elevation MI; TLR — target lesion revascularization; TVR — target vessel revascularization; UAP — un-
stable angina pectoris.
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Table 4. Independent predictors of primary endpoint according to clinical presentation.
HR (95% CI) Beta coefficient P
Overall
Gender (women) 0.78 (0.65–0.94) –0.243 0.009
Age 1.08 (1.07–1.09) < 0.001 0.080
Previous DM 1.63 (1.39–1.93) 0.491 < 0.001
Smoking 1.32 (1.08–1.60) 0.277 0.006
Previous MI 1.53 (1.14–2.05) 0.422 0.005
Previous CHF 3.22 (2.45–4.23) 1.169 < 0.001
Previous PVD 1.74 (1.18–2.57) 0.554 0.005
Multivessel disease 1.47 (1.21–1.78) 0.382 < 0.001
Left main disease 1.56 (1.15–2.11) 0.444 0.004
Stent diameter 0.73 (0.59–0.92) –0.308 0.007
SAP
Age 1.08 (1.06–1.10) 0.079 < 0.001
Diabetes 1.48 (1.09–1.99) 0.390 0.011
Previous MI 1.94 (1.16–3.26) 0.664 0.012
Previous CHF 4.52 (2.88–7.08) 1.508 0.000
Previous PVD 2.03 (1.09–3.76) 0.706 0.025
Multivessel disease 1.46 (1.03–2.07) 0.378 0.034
UAP/NSTEMI
Gender (women) 0.69 (0.53–0.89) –0.375 0.005
Age 1.09 (1.08–1.11) 0.089 < 0.001
Diabetes 1.88 (1.47–2.40) 0.630 0.000
Smoking 1.38 (1.03–1.84) 0.319 0.032
Previous CHF 2.86 (1.93–4.24) 1.052 0.000
Multivessel disease 1.58 (1.16–2.15) 0.457 0.004
Bifurcation 1.37 (1.05–1.80) 0.316 0.022
Stent diameter 0.68 (0.49–0.95) –0.387 0.023
Use of IVUS 0.72 (0.54–0.95) –0.334 0.018
STEMI
Age 1.07 (1.05–1.08) 0.064 < 0.001
Diabetes 1.60 (1.13–2.28) 0.472 0.009
Left main disease 2.93 (1.49–5.77) 1.076 0.002
No. of stents 0.55 (0.32–0.94) –0.603 0.029
Stent diameter 0.62 (0.38–1.00) –0.482 0.048
HR — hazard ratio; CI — confidence interval; SAP — stable angina pectoris; UAP — unstable angina pectoris; NSTEMI — non-ST-segment 
elevation MI; STEMI — ST-segment elevation MI; MI — myocardial infarction; CHF — congestive heart failure; PVD — peripheral vascular dis-
ease; IVUS — intravascular ultrasound
that the greater risk of long-term mortality with 
women occurred only in STEMI, whilst mortal-
ity with other clinical presentations were similar 
between the sexes [14, 26]. One of our previous 
studies on STEMI patients showed that the risk of 
death and cardiac death in women was significantly 
higher than in men; however, after adjustment for 
differences in baseline characteristics, the risk 
became similar [17].
In the present study, for women, crude cardiac 
mortality was observed in 3.0% in SAP, 3.7% in 
UAP/NSTEMI, and 7.9% in STEMI, which is simi-
lar to results of a previous study showing 3.5% in 
SAP, 3.7% in UAP/NSTEMI, and 6.4% in STEMI 
[26]. In the comparison of women vs. men, SAP 
and UAP/NSTEMI patients had similar adverse 
event rates between the sexes, while in STEMI 
patients, women had a higher risk of all-cause 
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death, cardiac death, and minor bleeding. Earlier 
trials consistently showed a higher incidence of 
minor bleeding with women than with men, with 
this effect not seen for major bleeding [27–29]. Our 
data confirmed this finding. Nevertheless, minor 
bleeding is of clinical relevance because it leads 
to medical intervention and influences treatment 
adherence and health care costs.
Further analysis was conducted to ascertain 
if there were any confounding factors that could 
affect clinical outcomes. Our study reported the 
effect of different adjustment models with age, 
baseline cardiovascular risk factors, and angio-
graphic/procedural risk factors and showed that 
outcomes were highly age dependent. Contrary to 
the unadjusted model, the adjusted results showed 
lower risk in women compared with men for UAP/ 
/NSTEMI patients, while there were no sex dif-
ferences in SAP and STEMI patients. In STEMI 
patients, women had a higher rate of the primary 
endpoint than men (HR 1.84, 95% CI 1.29–2.62, 
p = 0.001) at 3-year follow-up. However, adjusted 
results showed no difference between the sexes 
(HR 0.91, 95% CI 0.62–1.33, p = 0.631). Several 
long-term outcome studies for STEMI patients 
also reported that women had an increased risk 
compared to men, but the difference disappeared 
after the adjustment for covariates [15, 30–33]. 
Because the sex differences in long-term outcomes 
may vary with many confounding factors, the effect 
of each factor and multifactorial effect should be 
scrutinized with further research.
Although the GRAND-DES registry enrolled 
a non-selected population and is thus reflective of 
real-world cardiovascular care, and multivariable 
adjustment was performed for significant confound-
ers, it is possible that unmeasured confounders 
may affect our results. Therefore, we need to 
interpret them with caution.
Conclusions
In conclusion, there was no sex difference in 
cardiac death after PCI with DES for SAP and UAP/ 
/NSTEMI patients. In STEMI patients, women had 
worse outcomes compared with men; however, af-
ter the adjustment of confounders, female sex was 
not an independent predictor of mortality. 
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